[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@Generic_Tina Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1511682976639119365.png) @Generic_Tina Tina Banerjee

Tina Banerjee posts on X about japan, $8750t, $4503t, gilead sciences the most. They currently have XX followers and XXX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::1511682976639119365/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:interactions.svg)

- X Week XXX -XXXX%
- X Month XXX -XXXX%
- X Months XXXXX +106%
- X Year XXXXXX +333%

### Mentions: X [#](/creator/twitter::1511682976639119365/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:posts_active.svg)

- X Week XX +21%
- X Month XX -XX%
- X Months XXX +57%
- X Year XXX +258%

### Followers: XX [#](/creator/twitter::1511682976639119365/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:followers.svg)

- X Week XX +1.90%
- X Month XX -XXXX%
- X Months XX +23%

### CreatorRank: undefined [#](/creator/twitter::1511682976639119365/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1511682976639119365/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1511682976639119365/influence)
---

**Social category influence**
[countries](/list/countries)  XXXX% [finance](/list/finance)  XXXX% [stocks](/list/stocks)  XXXX%

**Social topic influence**
[japan](/topic/japan) 1.16%, [$8750t](/topic/$8750t) #23, [$4503t](/topic/$4503t) 0.39%, [gilead sciences](/topic/gilead-sciences) 0.39%, [sanofi](/topic/sanofi) 0.39%, [has been](/topic/has-been) 0.39%, [$206m](/topic/$206m) 0.39%, [$800820m](/topic/$800820m) 0.39%, [$770800m](/topic/$770800m) 0.39%, [$288308m](/topic/$288308m) XXXX%

**Top accounts mentioned or mentioned by**
[@smartkarma](/creator/undefined)

**Top assets mentioned**
[Gilead Sciences, Inc. (GILD)](/topic/gilead-sciences) [Sanofi (SNY)](/topic/sanofi)
### Top Social Posts [#](/creator/twitter::1511682976639119365/posts)
---
Top posts by engagements in the last XX hours

"Astellas Pharma's Izervay receives conditional approval in Japan for age-related macular degeneration. Izervay witnessed record high sales in Q1FY26 and a revenue growth of XX% is expected for FY26"  
[X Link](https://x.com/Generic_Tina/status/1973909683137282450) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-03T00:35Z XX followers, XX engagements


"Daiichi Sankyos label expansion application for Enhertu has been accepted by FDA. Hanmi Pharm entered into global licensing agreement with Gilead Sciences. Boryung is acquiring Taxotere from Sanofi"  
[X Link](https://x.com/Generic_Tina/status/1974634457497030897) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-05T00:35Z XX followers, XX engagements


"Telix Pharmaceuticals reports 3Q25 revenue of $206M up XX% YoY and X% QoQ. The company raised 2025 revenue guidance to $800820M from $770800M indicating 4Q25 revenue of $288308M up XX% QoQ"  
[X Link](https://x.com/Generic_Tina/status/1978620753336770678) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-16T00:35Z XX followers, XX engagements


"BeiGene reported strong 2Q25 revenues of $1.3B driven by Brukinsa sales in US and Europe. U.S. Brukinsa sales outpaced competitor for three consecutive quarters. Revenue guidance for 2025 increased"  
[X Link](https://x.com/Generic_Tina/status/1962405497564487853) [@Generic_Tina](/creator/x/Generic_Tina) 2025-09-01T06:41Z XX followers, XX engagements


"3SBio saw X% revenue decline in 1H25 with core product Tpiao sales dropping 4%. Phase III trials for three new drugs are complete and are under regulatory review"  
[X Link](https://x.com/Generic_Tina/status/1963400443834634248) [@Generic_Tina](/creator/x/Generic_Tina) 2025-09-04T00:35Z XX followers, XX engagements


"Xuanzhu Biopharmaceutical files for IPO to raise HK$781M. 2026 is a crucial year for the company's commercialization efforts. Lacks product differentiation which can ensure sustainable market play"  
[X Link](https://x.com/Generic_Tina/status/1976083993520140514) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-09T00:35Z XX followers, XX engagements


"SEBI has approved IHH Healthcares open offer for acquisition of up to XX% stake in Fortis Healthcare. If materializes this should uplift IHHs holding in Fortis to 57%"  
[X Link](https://x.com/Generic_Tina/status/1976446401489064301) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-10T00:35Z XX followers, XX engagements


"InnoCare stuck outlicensing deal with Zenas Bio. Daiichi Sankyo filed for label expansion of Enhertu in Japan. Celltrion got FDA nod for Eylea biosimilar. Lupin to build manufacturing plant in Florida"  
[X Link](https://x.com/Generic_Tina/status/1977171171197305161) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-12T00:35Z XX followers, XX engagements


"Sumitomo Pharma partners with Knight Therapeutics for exclusive licensing agreements in Canada and with Novo Nordisk in Japan for co-promotion of Ozempic leading to positive stock performance"  
[X Link](https://x.com/Generic_Tina/status/1978661813551239638) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-16T03:18Z XX followers, XX engagements


"Top Glove Corp's revenue grew XX% YoY to RM 3.5B in FY25 driven by a XX% increase in sales volume amid competitive pricing. Positive outlook on stock as margin improved alongside volume growth"  
[X Link](https://x.com/Generic_Tina/status/1978983108612624775) [@Generic_Tina](/creator/x/Generic_Tina) 2025-10-17T00:35Z XX followers, XX engagements